Dyne Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Dyne Therapeutics kazanç ve gelirin sırasıyla yıllık 37.7% ve 59.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 39.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -127.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

37.7%

Kazanç büyüme oranı

39.71%

EPS büyüme oranı

Biotechs kazanç büyümesi	23.0%
Gelir büyüme oranı	59.9%
Gelecekteki özkaynak getirisi	-127.58%
Analist kapsamı	Good
Son güncelleme	22 Dec 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

Jun 17

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 13

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Feb 28

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:DYN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	367	-316	-413	-380	7
12/31/2027	80	-454	-477	-434	9
12/31/2026	N/A	-498	-495	-457	13
12/31/2025	N/A	-447	-409	-382	13
9/30/2025	N/A	-424	-397	-376	N/A
6/30/2025	N/A	-413	-362	-360	N/A
3/31/2025	N/A	-367	-323	-320	N/A
12/31/2024	N/A	-317	-295	-292	N/A
9/30/2024	N/A	-295	-244	-243	N/A
6/30/2024	N/A	-258	-220	-219	N/A
3/31/2024	N/A	-257	-220	-220	N/A
12/31/2023	N/A	-236	-189	-188	N/A
9/30/2023	N/A	-208	-184	-182	N/A
6/30/2023	N/A	-189	-176	-175	N/A
3/31/2023	N/A	-177	-152	-150	N/A
12/31/2022	N/A	-168	-157	-154	N/A
9/30/2022	N/A	-181	-157	-153	N/A
6/30/2022	N/A	-182	-141	-137	N/A
3/31/2022	N/A	-160	-157	-152	N/A
12/31/2021	N/A	-149	-123	-120	N/A
9/30/2021	N/A	-126	-114	-112	N/A
6/30/2021	N/A	-97	-98	-96	N/A
3/31/2021	N/A	-77	-59	-58	N/A
12/31/2020	N/A	-59	-48	-47	N/A
9/30/2020	N/A	-36	-32	-30	N/A
6/30/2020	N/A	-28	-23	-22	N/A
3/31/2020	N/A	-21	-18	-17	N/A
12/31/2019	N/A	-15	-13	-12	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DYN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: DYN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: DYN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: DYN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: DYN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: DYN 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/01/02 04:22
Gün Sonu Hisse Fiyatı	2026/01/02 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Dyne Therapeutics, Inc. 24 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
William Pickering	Bernstein
Keay Nakae	Chardan Capital Markets, LLC

Dyne Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 10% to US$39.00

Price target decreased by 8.3% to US$36.32

Price target decreased by 8.4% to US$40.35

Price target increased by 8.9% to US$50.00

Price target increased by 8.3% to US$37.56

Price target increased by 9.6% to US$28.50

Recent updates

Dyne Therapeutics, Inc. Announces the Appointment of Vikram Karnani to Its Board of Directors

Price target increased by 10% to US$39.00

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350.000014 million.

Dyne Therapeutics, Inc. Announces Topline Results from Registrational Expansion Cohort of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Insufficient new directors

Dyne Therapeutics, Inc. Appoints Brian Posner to Its Board of Directors

Dyne Therapeutics, Inc. Announces Fda Breakthrough Therapy Designation for Dyne-251 in Duchenne Muscular Dystrophy (Dmd)

Price target decreased by 8.3% to US$36.32

CEO, President & Director recently bought US$911k worth of stock

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000006 million.

Price target decreased by 8.4% to US$40.35

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

Dyne Therapeutics, Inc., Annual General Meeting, May 30, 2025

Dyne Therapeutics, Inc. Announces New Long-Term Clinical Data from Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

New major risk - Shareholder dilution

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics to Present Data from the Ongoing DELIVER Clinical Trial in Duchenne Muscular Dystrophy At Upcoming Presentations At the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics: Moving Forward On 2 Key Fronts

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

New minor risk - Share price stability

Dyne Therapeutics, Inc. Announces New Clinical Data from Its Ongoing Phase 1/2 Achieve Trial of Dyne-10 in Patients with Myotonic Dystrophy Type 1 (DM1)

New minor risk - Insider selling

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member